ECSP088456A - Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias - Google Patents

Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias

Info

Publication number
ECSP088456A
ECSP088456A EC2008008456A ECSP088456A ECSP088456A EC SP088456 A ECSP088456 A EC SP088456A EC 2008008456 A EC2008008456 A EC 2008008456A EC SP088456 A ECSP088456 A EC SP088456A EC SP088456 A ECSP088456 A EC SP088456A
Authority
EC
Ecuador
Prior art keywords
cancer
treatment
pirimidn
tiofen
amina
Prior art date
Application number
EC2008008456A
Other languages
English (en)
Spanish (es)
Inventor
Q May Wang
Karl Robert Dahnke
Ho-Shen Lin
Michael Enrico Richett
Chuan Shih
Bo Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP088456A publication Critical patent/ECSP088456A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2008008456A 2005-11-18 2008-05-16 Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias ECSP088456A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
ECSP088456A true ECSP088456A (es) 2008-06-30

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008456A ECSP088456A (es) 2005-11-18 2008-05-16 Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias

Country Status (27)

Country Link
US (1) US7547691B2 (en.when)
EP (1) EP1989200B1 (en.when)
JP (1) JP2009516697A (en.when)
KR (1) KR100990771B1 (en.when)
CN (1) CN101309918B (en.when)
AR (1) AR057911A1 (en.when)
AT (1) ATE437873T1 (en.when)
AU (1) AU2006337626B2 (en.when)
BR (1) BRPI0618245A2 (en.when)
CA (1) CA2629336A1 (en.when)
CR (1) CR9947A (en.when)
DE (1) DE602006008187D1 (en.when)
DK (1) DK1989200T3 (en.when)
EA (1) EA014426B1 (en.when)
EC (1) ECSP088456A (en.when)
ES (1) ES2329085T3 (en.when)
IL (1) IL190489A0 (en.when)
MA (1) MA30053B1 (en.when)
NO (1) NO20082594L (en.when)
PE (1) PE20070833A1 (en.when)
PL (1) PL1989200T3 (en.when)
PT (1) PT1989200E (en.when)
SI (1) SI1989200T1 (en.when)
TN (1) TNSN08227A1 (en.when)
TW (1) TW200800201A (en.when)
WO (1) WO2007092095A2 (en.when)
ZA (1) ZA200803940B (en.when)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007752B1 (en) 2006-03-31 2010-08-18 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
WO2008011560A2 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
BRPI0721045A2 (pt) * 2006-12-21 2014-07-29 Lilly Co Eli Compostos de aminopirimidina de imidazolidinonila para o tratamento do câncer
JP2010513553A (ja) * 2006-12-21 2010-04-30 イーライ リリー アンド カンパニー 癌治療用イミダゾリジノニルアミノピリミジン化合物
JP5248600B2 (ja) 2007-05-16 2013-07-31 イーライ リリー アンド カンパニー トリアゾリルアミノピリミジン化合物
CN101679396B (zh) 2007-05-16 2012-06-06 伊莱利利公司 三唑基氨基嘧啶化合物
TWI481603B (zh) 2008-06-30 2015-04-21 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
CN102858764B (zh) 2010-04-27 2014-08-20 和记黄埔医药(上海)有限公司 嘧啶基吲哚化合物
WO2013058824A1 (en) 2011-04-07 2013-04-25 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
US10189825B2 (en) 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
IL264446B2 (en) 2016-07-29 2024-09-01 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
SG11201900687VA (en) 2016-07-29 2019-02-27 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
US11358959B2 (en) * 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
ES2397362T3 (es) * 2004-12-17 2013-03-06 Amgen Inc. Compuestos de aminopirimidina como inhibidores de PLK

Also Published As

Publication number Publication date
DK1989200T3 (da) 2009-11-09
US7547691B2 (en) 2009-06-16
IL190489A0 (en) 2008-11-03
NO20082594L (no) 2008-06-10
KR100990771B1 (ko) 2010-10-29
WO2007092095A2 (en) 2007-08-16
JP2009516697A (ja) 2009-04-23
DE602006008187D1 (de) 2009-09-10
TW200800201A (en) 2008-01-01
PL1989200T3 (pl) 2009-12-31
WO2007092095A3 (en) 2007-11-08
ZA200803940B (en) 2009-09-30
TNSN08227A1 (en) 2009-10-30
ATE437873T1 (de) 2009-08-15
PE20070833A1 (es) 2007-08-27
AU2006337626B2 (en) 2012-03-22
BRPI0618245A2 (pt) 2011-08-23
PT1989200E (pt) 2009-10-12
CR9947A (es) 2008-11-28
ES2329085T3 (es) 2009-11-20
EP1989200B1 (en) 2009-07-29
AU2006337626A8 (en) 2008-06-19
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
MA30053B1 (fr) 2008-12-01
US20080306082A1 (en) 2008-12-11
EP1989200A2 (en) 2008-11-12
KR20080059451A (ko) 2008-06-27
CN101309918B (zh) 2010-12-29
CN101309918A (zh) 2008-11-19
EA200801362A1 (ru) 2009-02-27
SI1989200T1 (sl) 2009-12-31
EA014426B1 (ru) 2010-12-30
AR057911A1 (es) 2007-12-26

Similar Documents

Publication Publication Date Title
ECSP088456A (es) Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
ECSP109882A (es) Derivados de 1-cianociclopropilo como inhibidores de la catepsina k
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
CR20140392A (es) Dihidropirazolonas sustituidas
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
SMAP201100019A (it) Composti organici.
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
UY33000A (es) Derivados de sulfonamida heterocíclicos
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
UY32748A (es) 2-carboxamida-cicloamino-ureas
NI201200100A (es) Derivados de sulfonamida heterocíclicos
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
NZ596158A (en) Thioxanthene derivatives for the treatment of infectious diseases